Signum, GSK in R&D Pact

Signum Biosciences has entered into an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to collaborate on Signum’s phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).

Signum will receive research support and milestone payments. GSK will have exclusive rights to Signum’s phosphatase screening technology for R&D activities in neurosciences. Both companies will screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation.

Maxwell Stock, president of Signum, said, “GSK is an ideal partner for Signum. We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies. We are proud to be working in collaboration with a leading pharmaceutical company in innovative R&D. Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug.”